Skip to content
DataLookout
Menu

NCT07798609

A Trial to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of SFL-0821 in Adults With FSHD

StatusRecruiting
PhasePhase 1/2
Primary completion (estimated)

At risk: Primary completion moved at least 1 year 4 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 10 versions: 10 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion dates pushed to Aug 2029
    • Start date changed from estimate of Sep 2026 to Oct 14, 2026
    • Site contacts updated at 1 of 6 sites
  2. Minor Site contacts updated at 1 of 6 sites
  3. Minor Site details revised at 1 of 6 sites
  4. Notable Eligibility criteria expanded, about 7 words
    • Secondary endpoints: 10 to 12
    • Site contacts updated at 1 of 6 sites
  5. Minor Site details revised at 1 of 6 sitesv6
  6. Notable Recruitment opened
    • Site details revised at 6 of 6 sites
    v5
  7. Minor Site contacts updated at 5 of 6 sitesv4
  8. Minor Site contacts updated at 1 of 6 sitesv3
  9. Minor Study sites: 7 to 6v2
  10. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Number of participants with treatment-emergent adverse events, serious adverse events, and any other dose-limiting toxicities as assessed by CTCAE v6.0.
Timeframe: Part A: Up to Week 24; Part B: Up to Week 48

Secondary (12)

Pharmacokinetics of SFL-0821: Maximum Observed Plasma Concentration (Cmax)
Pharmacokinetics of SFL-0821: Elimination half-life (T1/2 [h])
Pharmacokinetics of SFL-0821: Area under the concentration-time curve (AUC)
DUX4-regulated gene expression in skeletal muscle
Incidence of anti-drug antibodies (ADAs), and if positive, of neutralizing ADAs
Show 7 moreShow less
Change from Baseline in quantitative skeletal muscle magnetic resonance imaging (MRI) at the cohort specified timepoints after dosing
Change from Baseline to Week 48 in 10-Meter Walk-Run-Test (10MWRT)
Change from Baseline to Week 48 in Timed Up-and-Go (TUG) Test
Change from Baseline to Week 48 in 4-Step Stair Climb Test
Change from Baseline to Week 48 in Sit-to-Stand Test
Change from Baseline to Week 48 in Reachable Workspace (RWS)
Change from Baseline to Week 48 in quantitative muscle strength testing

Arms and interventions

SFL-0821Experimental

SFL-0821 for Injection

PlaceboPlacebo comparator

Placebo for Injection

Drugs: SFL-0821 for injection, Placebo

Sites

6 sites in 2 countries

Australia 5, New Zealand 1